Indivior PLC(INDV) - 2023 Q3 - Quarterly Report

November 9, 2023 Strong Top-line Performance and Strategic Progress in Q3 2023 • FY 2023 SUBLOCADE NR now expected to be $610m to$630m (vs. $590m to$630m) • OPVEE® launched; U.S. Biomedical Advanced Research and Development Authority (BARDA) contract secured Period to September 30th (Unaudited) Q3 2023 $m Q3 2022$m % Change YTD 2023 $m YTD 2022$m % Change Net Revenue 271 232 17% 800 659 21% Operating (Loss)/Profit (183) 56 NM (65) 173 NM Net (Loss)/Income (135) 41 NM (52) 130 NM Diluted (LPS)/EPS ($)$( ...